NEW YORK (GenomeWeb) – A negative coverage recommendation proposed by the Oregon Health Authority could restrict access to next-generation sequencing tumor profiling for some of the most vulnerable residents in the state, cancer patient advocates fear.
Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.